The Expressions of Somatostatin and Cycloxygenase-2 in Chronic Hepatitis. Hepatic Cirrhosis. Precancerous Lesion and Hepatocellular Carcinoma

XIE Yong-mei, LI Xiao, YAN Lyu-nan. et al

Abstract

To investigate the expression difference of somatostatin (SST), SST receptors (SSTR) and COX-2 in chronic hepatitis, hepatic cirrhosis, precancerous lesion and hepatocellular Carcinoma, and explore the relationship between portal hypertension and SST/SSTR expressions. Methods A series of human liver tissues were obtained from surgery, including normal liver 4 cases, chronic hepatitis 14 cases, hepatic cirrhosis 40 cases, precancerous lesion 40 cases and HCC tissues 40 cases. Peripheral bloods were collected from 20 patients before and after the operation of transjugular intrahepatic portosystemic shunt (TIPS). SSTR 1-5 subtypes in hepatic tissues were detected by immunohistochemical study and RT-PCR. Levels of SST and COX-2 were quantified by radioimmunoassay and Western blot. Results 90% of precancerosis expressed high levels of SSTR 2,5 subtypes, and SSTR mainly distributed surrounding portal vein. At lest 60% of HCC expressed SSTR 2,5 subtypes, and there were positive correlations between levels of SSTR 1-5 and SST. Levels of SST in peripheral blood of cirrhotic patients significantly increased after TIPS（ P<0.05）. Levels of COX-2 were highest in cirrhosis (about 90%), and decreased in precancerosis (about 80%) and HCC tissues. Conclusions Precancerosis or early stage of HCC may be the optimum time for synergetic medication of SST analogue and COX-2 inhibitor.

 

Keywords: Hepatocellular carcinoma, Somatostatin, Cyclooxygenase-2, Portal hypertension


Full Text:

PDF


References


Xie Y, Chen S. Wang CH. et al. SQM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts. Cancer Biol Ther.2011; 12( 1):86-92.

Wang CH. Zheng WB, Qiang O, et al. Effects of non- cytotoxic drugs on the growth of multidrug-resistance human gastric carcinoma cell line. J Dig Dis,2009; 10(2);91 -98.

Borbath I, Leclercq IA, Sempoux C, et al. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chem Biol Interact, 2010; 183 (1):238-248.

Hossain MA, Kim DH, Jang JY. et al. Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in -vivo. Int J Oncol,2012;40(5): 1636-1642.

Song HJ, Kim YS, Han CH. et al. A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor. Korean J Hepatol,2006; 12(3) ;449-454.

Roncalli M, Borzio M, Di Tommaso L. Hepatocellular dysplastic nodules. Ann Ital Chir,2008; 79(2);81-89.

War SA, Somvanshi RK. Kumar U. Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochim Biophys Acta, 2011 $ 1813 ( 3) : 390-402.

Borbath I, Leclercq I A, Sempoux C, et al. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chem Biol Interact,2010; 183 (1): 238-248.

Ji XQ. Ruan XJ, Chen H. et al. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit .2011; 17(8):RA169-RA176.

Borbath 1, Lhommel R, Guiot Y, et al. Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival. Acta Gastroenterol Belg.2012;75(2) :270-273.

Shah U, O’Neil B, Allen J, et al. A phase Ц study of long- acting octreotide in patients with advanced hepatocellular carcinoma and CLIP score of 3 or higher. Gastrointest Cancer Res,2009;3(2);45-48.

Patel RC, Kumar U, Lamb DC, et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci U S A,2002;99(5): 3294-3299.

Samonakis DN, Notas G. Christodoulakis N, et al. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci,2008;53(9) s2359-2365.

Ma D, Liu M, Wang AP, et at. Cycloxygenase-2 is essential for the survival and proliferation of gastric cancer cells. Cell Biochem Biophys, 2011; 61 (3) s 637-641.

Kern MA, Schubert D, Sahi D, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology, 2002; 36 (4 Pt 1) ; 885-894.

Fernandez-Alvarez A, Llorente-Izquierdo C, Mayoral R, et al. Evaluation of epigenetic modulation of cyclooxygenase-2 as a prognostic marker for hepatocellular carcinoma. Oncogenesis, 2012; 1(7): e23. doi: 10. 1038/oncsis. 2012. 23.

Qiu DK. Ma X, Peng YS, et al. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J Gastroenterol,2002;8(5):815-817.

Qiu DK. Ma X, Peng YS, et al. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J Gastroenterol,2002;8(5):815-B17.

Tong H. Li X, Zhang CL, et al. Octreotide and celecoxib synergistically encapsulate VX2 hepatic allografts following transcatheter arterial embolisation. Exp Ther Med.2013;5(3); 777-7782.

Alderton F, Fan TP, Humphrey PP. Somatostatin receptor- mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides. Br J Pharmacol, 2001 ; 132( 3); 760-766.


Refbacks

  • There are currently no refbacks.